To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

PHASE3CompletedINTERVENTIONAL

Enrollment

567

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2025

Conditions

Overweight or Obesity

Interventions

DRUG

HRS9531 injection

HRS9531 injection; low dose

DRUG

HRS9531 injection

HRS9531 injection; medium dose

DRUG

HRS9531 injection

HRS9531 injection, high dose

DRUG

Placebo

blank preparation, participants received matching placebo.

Trial Locations (1)

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06396429 - To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese | Biotech Hunter | Biotech Hunter